Bray, F. et al. Global Cancer Statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74, 229–263 (2024).
Sonkin, D., Thomas, A. & Teicher, B. A. Cancer treatments: past, present, and future. Cancer Genet 286–287, 18–24 (2024)..
Liu, B., Zhou, H., Tan, L., Siu, K. T. H. & Guan, X. Y. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther 9, 175 (2024).
Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov 12, 31–46 (2022).
Zhang, M. et al. Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. Mol Cancer 24, 136 (2025).
Tufail, M., Jiang, C. H. & Li, N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduct Target Ther 10, 227 (2025).
Roerden, M. & Spranger, S. Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat Rev Immunol 25, 353–369 (2025).
Verdys, P. et al. Acquired resistance to immunotherapy in solid tumors. Trends Mol Med 31, 1008–1020 (2025).
Winkler, F. et al. Cancer neuroscience: state of the field, emerging directions. Cell 186, 1689–1707 (2023).
Pu, T., Sun, J., Ren, G. & Li, H. Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications. Signal Transduct Target Ther 10, 176 (2025).
Irwin, M. R. & Cole, S. W. Reciprocal regulation of the neural and innate immune systems. Nat Rev Immunol 11, 625–632 (2011).
Wallrapp, A. & Chiu, I. M. Neuroimmune interactions in the intestine. Annu Rev Immunol 42, 489–519 (2024).
Kawashima, K., Fujii, T., Moriwaki, Y. & Misawa, H. Critical roles of acetylcholine and the muscarinic and nicotinic acetylcholine receptors in the regulation of immune function. Life Sci 91, 1027–1032 (2012).
Udit, S., Blake, K. & Chiu, I. M. Somatosensory and autonomic neuronal regulation of the immune response. Nat Rev Neurosci 23, 157–171 (2022).
Strickland, M. R., Alvarez-Breckenridge, C., Gainor, J. F. & Brastianos, P. K. Tumor immune microenvironment of brain metastases: toward unlocking antitumor immunity. Cancer Discov 12, 1199–1216 (2022).
García-Reyes, B. et al. Glial cell-derived soluble factors increase the metastatic potential of pancreatic adenocarcinoma cells and induce epithelial-to-mesenchymal transition. J Cancer Res Clin Oncol 149, 14315–14327 (2023).
Zhang, S., Chen, J., Cheng, F. & Zheng, F. The emerging role of Schwann cells in the tumor immune microenvironment and its potential clinical application. Int J Mol Sci. https://doi.org/10.3390/ijms252413722 (2024).
Chen, Q. et al. Carcinoma–astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature 533, 493–498 (2016).
Yuzhalin, A. E. et al. Astrocyte-induced Cdk5 expedites breast cancer brain metastasis by suppressing MHC-I expression to evade immune recognition. Nat Cell Biol 26, 1773–1789 (2024).
Vandenbark, A. A., Offner, H., Matejuk, S. & Matejuk, A. Microglia and astrocyte involvement in neurodegeneration and brain cancer. J Neuroinflamm 18, 298 (2021).
Geraldo, L. H. et al. SLIT2/ROBO signaling in tumor-associated microglia and macrophages drives glioblastoma immunosuppression and vascular dysmorphia. J Clin Invest. https://doi.org/10.1172/jci141083 (2021).
Liu, Y. et al. ITGA5-expressing tumor cells interact with Schwann cells to drive nerve growth factor-mediated immunosuppression of NK cells. Mol Ther 33, 5591–5610 (2025).
Allen, J. K. et al. Sustained adrenergic signaling promotes intratumoral innervation through BDNF induction. Cancer Res 78, 3233–3242 (2018).
Pundavela, J. et al. Nerve fibers infiltrate the tumor microenvironment and are associated with nerve growth factor production and lymph node invasion in breast cancer. Mol Oncol 9, 1626–1635 (2015).
Huber, R. M. et al. DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance. Oncotarget 6, 2134–2147 (2015).
Yang, D. et al. Progress, opportunity, and perspective on exosome isolation — efforts for efficient exosome-based theranostics. Theranostics 10, 3684–3707 (2020).
Madeo, M. et al. Cancer exosomes induce tumor innervation. Nat Commun 9, 4284 (2018).
Amit, M. et al. Loss of p53 drives neuron reprogramming in head and neck cancer. Nature 578, 449–454 (2020).
Livnat, S., Felten, S. Y., Carlson, S. L., Bellinger, D. L. & Felten, D. L. Involvement of peripheral and central catecholamine systems in neural–immune interactions. J Neuroimmunol 10, 5–30 (1985).
Haas, H. S. & Schauenstein, K. Neuroimmunomodulation via limbic structures — the neuroanatomy of psychoimmunology. Prog Neurobiol 51, 195–222 (1997).
Soto-Tinoco, E., Guerrero-Vargas, N. N. & Buijs, R. M. Interaction between the hypothalamus and the immune system. Exp Physiol 101, 1463–1471 (2016).
Reiche, E. M., Nunes, S. O. & Morimoto, H. K. Stress, depression, the immune system, and cancer. Lancet Oncol 5, 617–625 (2004).
Ben-Shaanan, T. L. et al. Modulation of anti-tumor immunity by the brain’s reward system. Nat Commun 9, 2723 (2018).
Aiello, I. et al. Circadian disruption promotes tumor-immune microenvironment remodeling favoring tumor cell proliferation. Sci Adv. https://doi.org/10.1126/sciadv.aaz4530 (2020).
Nillni, E. A. Regulation of the hypothalamic thyrotropin releasing hormone (TRH) neuron by neuronal and peripheral inputs. Front Neuroendocrinol 31, 134–156 (2010).
Dantzer, R. Neuroimmune interactions: from the brain to the immune system and vice versa. Physiol Rev 98, 477–504 (2018).
Vanden Abeele, F. & Salzet, M. The neuro-immune oncology axis. Cancer Lett 634, 218070 (2025).
Teratani, T. et al. The liver–brain–gut neural arc maintains the T(reg) cell niche in the gut. Nature 585, 591–596 (2020).
Rosas-Ballina, M. et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science 334, 98–101 (2011).
Gabanyi, I. et al. Neuro-immune interactions drive tissue programming in intestinal macrophages. Cell 164, 378–391 (2016).
Matheis, F. et al. Adrenergic signaling in muscularis macrophages limits infection-induced neuronal loss. Cell 180, 64–78.e16 (2020).
Wang, J. et al. The modulation of neuroimmune responses in peripheral inflammation. J Inflamm Res 18, 9015–9030 (2025).
Liu, K. et al. Sleep deprivation aggravates periodontitis through trigeminal-periodontal neuroimmune pathway mediated by the AChE–ACh–α7nAChR axis. Adv. Sci. 12, e00945 (2025).
Inoue, T. et al. Non-canonical cholinergic anti-inflammatory pathway-mediated activation of peritoneal macrophages induces Hes1 and blocks ischemia/reperfusion injury in the kidney. Kidney Int 95, 563–576 (2019).
Nguyen, H. H., Talbot, J., Li, D., Raghavan, V. & Littman, D. R. Modulating intestinal neuroimmune VIPergic signaling attenuates the reduction in ILC3-derived IL-22 and hepatic steatosis in MASLD. Hepatol. Commun. https://doi.org/10.1097/hc9.0000000000000528 (2024).
Silverman, D. A. et al. Cancer-associated neurogenesis and nerve-cancer cross-talk. Cancer Res 81, 1431–1440 (2021).
Zhang, Y. et al. Cancer cells co-opt nociceptive nerves to thrive in nutrient-poor environments and upon nutrient-starvation therapies. Cell Metab. 34, 1999–2017.e10 (2022).
Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12, 252–264 (2012).
Jiang, L. et al. Nociceptive adenosine A(2A) receptor on trigeminal nerves orchestrates CGRP release to regulate the progression of oral squamous cell carcinoma. Int J Oral Sci 16, 46 (2024).
Xu, Q. et al. Multiple cancer cell types release LIF and Gal3 to hijack neural signals. Cell Res. 34, 345–354 (2024).
He, K. et al. Activated Schwann cells promote tumor growth in colon cancer. Cancer Lett. 626, 217791 (2025).
Shurin, G. V., Vats, K., Kruglov, O., Bunimovich, Y. L. & Shurin, M. R. Tumor-induced T cell polarization by Schwann cells. Cells https://doi.org/10.3390/cells11223541 (2022).
Restaino, A. C. et al. Tumor-infiltrating nociceptor neurons promote immunosuppression. Sci. Signal 18, eads7889 (2025).
Liu, R. et al. Tumor cells induce neural DKK1 expression to promote MDSC infiltration and subsequent T cell suppression. Cell Signal 127, 111576 (2025).
Nejo, T. et al. Glioma-neuronal circuit remodeling induces regional immunosuppression. Nat Commun 16, 4770 (2025).
Sun, C. et al. Tumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion. Sci. Adv 9, eadd6995 (2023).
Baruch, E. N. et al. Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy. Nature https://doi.org/10.1038/s41586-025-09370-8 (2025).
Erin, N. et al. Activation of neuroimmune pathways increases therapeutic effects of radiotherapy on poorly differentiated breast carcinoma. Brain Behav Immun 48, 174–185 (2015).
Chen, M. M. et al. Integrated single-cell and spatial transcriptomics uncover distinct cellular subtypes involved in neural invasion in pancreatic cancer. Cancer Cell 43, 1656–1676.e10 (2025).
Fukuda, Y. et al. S100-stained perineural invasion is associated with worse prognosis in stage I/II colorectal cancer: its possible association with immunosuppression in the tumor. Pathol. Int. 72, 117–127 (2022).
Gysler, S. M. & Drapkin, R. Tumor innervation: peripheral nerves take control of the tumor microenvironment. J Clin Invest https://doi.org/10.1172/jci147276 (2021).
Khanmammadova, N., Islam, S., Sharma, P. & Amit, M. Neuro-immune interactions and immuno-oncology. Trends Cancer 9, 636–649 (2023).
Li, G. et al. Sciatic nerve stimulation enhances NK cell cytotoxicity through dopamine signaling and synergizes immunotherapy in triple-negative breast cancer. Drug Resist Updat 79, 101212 (2025).
Yoshida, S. et al. Elucidation of the mechanisms underlying tumor aggravation by the activation of stress-related neurons in the paraventricular nucleus of the hypothalamus. Mol Brain 16, 18 (2023).
Mardelle, U., Bretaud, N., Daher, C. & Feuillet, V. From pain to tumor immunity: influence of peripheral sensory neurons in cancer. Front Immunol 15, 1335387 (2024).
Sur, D. et al. Entangled cellular and molecular relationships at the sensory neuron–cancer interface. Neuron 113, 2760–2790 (2025).
Vats, K. et al. Sensory nerves impede the formation of tertiary lymphoid structures and development of protective antimelanoma immune responses. Cancer Immunol Res 10, 1141–1154 (2022).
Tao, Z. Y., Wang, L., Zhu, W. Y., Zhang, G. & Su, Y. X. Lingual denervation improves the efficacy of anti-PD-1 immunotherapy in oral squamous cell carcinomas by downregulating TGFβ signaling. Cancer Res. Commun 4, 418–430 (2024).
Xu, M., Yu, Y. & Cao, C. CGRP-mediated neural addiction in tumor dynamic remodeling. Trends Cancer 11, 834–838 (2025).
McIlvried, L. A., Atherton, M. A., Horan, N. L., Goch, T. N. & Scheff, N. N. Sensory neurotransmitter calcitonin gene-related peptide modulates tumor growth and lymphocyte infiltration in oral squamous cell carcinoma. Adv Biol. 6, e2200019 (2022).
Balood, M. et al. Nociceptor neurons affect cancer immunosurveillance. Nature 611, 405–412 (2022).
Tanaka, K. et al. Repeated activation of Trpv1-positive sensory neurons facilitates tumor growth associated with changes in tumor-infiltrating immune cells. Biochem Biophys Res. Commun 648, 36–43 (2023).
Erin, N., Akman, M., Aliyev, E., Tanrıöver, G. & Korcum, A. F. Olvanil activates sensory nerve fibers, increases T cell response and decreases metastasis of breast carcinoma. Life Sci 291, 120305 (2022).
Erin, N., Shurin, G. V., Baraldi, J. H. & Shurin M. R. Regulation of carcinogenesis by sensory neurons and neuromediators. Cancers https://doi.org/10.3390/cancers14092333 (2022)
Zheng, Y. et al. Mechanisms of neural infiltration-mediated tumor metabolic reprogramming impacting immunotherapy efficacy in non-small cell lung cancer. J Exp Clin Cancer Res. 43, 284 (2024).
Karmakar, S. & Lal, G. Role of serotonin receptor signaling in cancer cells and anti-tumor immunity. Theranostics 11, 5296–5312 (2021).
Zhi, X. et al. Nociceptive neurons promote gastric tumour progression via a CGRP–RAMP1 axis. Nature 640, 802–810 (2025).
Darragh, L. B. et al. Sensory nerve release of CGRP increases tumor growth in HNSCC by suppressing TILs. Med 5, 254–270.e8 (2024).
Zhang, H. et al. Intra-tumoural RAMP1+ B cells promote resistance to neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma. Immunother Adv 5, ltaf012 (2025).
Wang, K. et al. Nociceptor neurons promote PDAC progression and cancer pain by interaction with cancer-associated fibroblasts and suppression of natural killer cells. Cell Res 35, 362–380 (2025).
Fnu, T. et al. Sympathetic neurons promote small cell lung cancer through the β2-adrenergic receptor. Cancer Discov 15, 616–632 (2025).
Savchuk, S. et al. Neuronal activity-dependent mechanisms of small cell lung cancer pathogenesis. Nature 646, 1232–1242 (2025).
Sakthivelu, V. et al. Functional synapses between neurons and small cell lung cancer. Nature 646, 1243–1253 (2025).
Kang, F. et al. Propranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2. J Nucl Med 55, 439–445 (2014).
Le, C. P. et al. Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination. Nat Commun 7, 10634 (2016).
Kobayashi, H. et al. Neuro-mesenchymal interaction mediated by a β2-adrenergic nerve growth factor feedforward loop promotes colorectal cancer progression. Cancer Discov 15, 202–226 (2025).
Globig, A. M. et al. The β(1)-adrenergic receptor links sympathetic nerves to T cell exhaustion. Nature 622, 383–392 (2023).
Sun, C., Shen, Y., Wang, F., Lu, T. & Zhang, J. Sympathetic nervous system in tumor progression and metabolic regulation: mechanisms and clinical potential. J Transl Med 23, 836 (2025).
Gandhi, S. et al. Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: safety, tolerability, and preliminary evidence of antitumor activity. Clin Cancer Res 27, 87–95 (2021).
Thiel, V. et al. Characterization of single neurons reprogrammed by pancreatic cancer. Nature 640, 1042–1051 (2025).
Qiao, G. et al. β-Adrenergic signaling blocks murine CD8(+) T-cell metabolic reprogramming during activation: a mechanism for immunosuppression by adrenergic stress. Cancer Immunol Immunother 68, 11–22 (2019).
Estrada, L. D., Ağaç, D. & Farrar, J. D. Sympathetic neural signaling via the β2-adrenergic receptor suppresses T-cell receptor-mediated human and mouse CD8(+) T-cell effector function. Eur J Immunol 46, 1948–1958 (2016).
Wu, V. H. et al. The GPCR–Gα(s)–PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure. Nat Immunol 24, 1318–1330 (2023).
Wu, J. et al. Dopamine inhibits the function of Gr-1+CD115+ myeloid-derived suppressor cells through D1-like receptors and enhances anti-tumor immunity. J Leukoc Biol 97, 191–200 (2015).
Daher, C. et al. Blockade of β-adrenergic receptors improves CD8(+) T-cell priming and cancer vaccine efficacy. Cancer Immunol Res 7, 1849–1863 (2019).
Nissen, M. D., Sloan, E. K. & Mattarollo, S. R. β-Adrenergic signaling impairs antitumor CD8(+) T-cell responses to B-cell lymphoma immunotherapy. Cancer Immunol Res 6, 98–109 (2018).
Qiao, G. et al. Chronic adrenergic stress contributes to metabolic dysfunction and an exhausted phenotype in T cells in the tumor microenvironment. Cancer Immunol Res 9, 651–664 (2021).
Fu, S. et al. Regulatory mucosa-associated invariant T cells controlled by β1 adrenergic receptor signaling contribute to hepatocellular carcinoma progression. Hepatology 78, 72–87 (2023).
Qin, J. F. et al. Adrenergic receptor β2 activation by stress promotes breast cancer progression through macrophages M2 polarization in tumor microenvironment. BMB Rep 48, 295–300 (2015).
Ben-Eliyahu, S., Shakhar, G., Page, G. G., Stefanski, V. & Shakhar, K. Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and beta-adrenoceptors. Neuroimmunomodulation 8, 154–164 (2000).
Mohammadpour, H. et al. β2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells. J Clin Invest 129, 5537–5552 (2019).
Guillot, J. et al. Sympathetic axonal sprouting induces changes in macrophage populations and protects against pancreatic cancer. Nat Commun 13, 1985 (2022).
Chen, X. et al. Neurodegeneration of local sympathetic inputs promotes colorectal cancer progression. Cancer Lett 625, 217817 (2025).
Zhu, J. et al. Tumour immune rejection triggered by activation of α2-adrenergic receptors. Nature 618, 607–615 (2023).
Partecke, L. I. et al. Subdiaphragmatic vagotomy promotes tumor growth and reduces survival via TNFα in a murine pancreatic cancer model. Oncotarget 8, 22501–22512 (2017).
Zhang, Z. et al. Electroacupuncture regulates inflammatory cytokines by activating the vagus nerve to enhance antitumor immunity in mice with breast tumors. Life Sci 272, 119259 (2021).
Renz, B. W. et al. Cholinergic signaling via muscarinic receptors directly and indirectly suppresses pancreatic tumorigenesis and cancer stemness. Cancer Discov 8, 1458–1473 (2018).
Wang, Z., Liu, W., Wang, C., Li, Y. & Ai, Z. Acetylcholine promotes the self-renewal and immune escape of CD133+ thyroid cancer cells through activation of CD133-Akt pathway. Cancer Lett 471, 116–124 (2020).
Kuol, N. et al. Blocking muscarinic receptor 3 attenuates tumor growth and decreases immunosuppressive and cholinergic markers in an orthotopic mouse model of colorectal cancer. Int J Mol Sci. https://doi.org/10.3390/ijms24010596 (2022).
Bonaz, B., Sinniger, V. & Pellissier, S. The vagus nerve in the neuro-immune axis: implications in the pathology of the gastrointestinal tract. Front Immunol 8, 1452 (2017).
Belo, A. et al. Muscarinic receptor agonists stimulate human colon cancer cell migration and invasion. Am J Physiol Gastrointest Liver Physiol 300, G749–G760 (2011).
Pinho-Ribeiro, F. A., Verri, W. A. Jr & Chiu, I. M. Nociceptor sensory neuron-immune interactions in pain and inflammation. Trends Immunol 38, 5–19 (2017).
Zhang, Z., Li, Y., Lv, X., Zhao, L. & Wang X. VLM catecholaminergic neurons control tumor growth by regulating CD8(+) T cells. Proc Natl Acad Sci USA https://doi.org/10.1073/pnas.2103505118 (2021).
Yu, S. et al. Depression decreases immunity and PD-L1 inhibitor efficacy via the hypothalamic–pituitary–adrenal (HPA) axis in triple-negative breast cancer. Biochim Biophys Acta Mol Basis Dis 1871, 167581 (2025).
Mauffrey, P. et al. Progenitors from the central nervous system drive neurogenesis in cancer. Nature 569, 672–678 (2019).
Pan, S. et al. Stimulation of hypothalamic oxytocin neurons suppresses colorectal cancer progression in mice. eLife https://doi.org/10.7554/eLife.67535 (2021)
Chen, M. et al. The rostral ventromedial and lateral medulla are the major areas responsive to lung cancer progression among brainstem lung-innervating nuclei. Brain Sci. https://doi.org/10.3390/brainsci12111486 (2022).
Channer, B. et al. Dopamine, immunity, and disease. Pharmacol Rev 75, 62–158 (2023).
Grant, C. E., Flis, A. L. & Ryan, B. M. Understanding the role of dopamine in cancer: past, present and future. Carcinogenesis 43, 517–527 (2022).
Staley, A. et al. Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer. Am J Cancer Res. 11, 5374–5387 (2021).
Lin, A. L. et al. The treatment of aggressive prolactinomas with everolimus. Pituitary 26, 474–481 (2023).
Yin, T. et al. Dopamine receptor antagonist thioridazine inhibits tumor growth in a murine breast cancer model. Mol Med Rep. 12, 4103–4108 (2015).
Figueroa, C. et al. Inhibition of dopamine receptor D3 signaling in dendritic cells increases antigen cross-presentation to CD8(+) T-cells favoring anti-tumor immunity. J Neuroimmunol 303, 99–107 (2017).
Wu, Y. et al. DA-DRD5 signaling reprograms B cells to promote CD8(+) T cell-mediated antitumor immunity. Cell Rep. 44, 115364 (2025).
Chen, Y. et al. Dopamine signaling promotes tissue-resident memory differentiation of CD8+ T cells and antitumor immunity. Cancer Res 82, 3130–3142 (2022).
Chovar-Vera, O. et al. Dopaminergic signalling enhances IL-2 production and strengthens anti-tumour response exerted by cytotoxic T lymphocytes in a melanoma mouse model. Cells https://doi.org/10.3390/cells11223536 (2022).
Xu, L. et al. Neuro–immune–tumor axis in gliomas: a review of mechanisms, models, and translational opportunities. Front Immunol 16, 1682322 (2025).
Tetzlaff, S. K. et al. Characterizing and targeting glioblastoma neuron–tumor networks with retrograde tracing. Cell 188, 390–411.e36 (2025).
Yang, Y. et al. Long-range cholinergic input promotes glioblastoma progression. Cancer Cell https://doi.org/10.1016/j.ccell.2025.07.024 (2025).
Taylor, K. R. et al. Glioma synapses recruit mechanisms of adaptive plasticity. Nature 623, 366–374 (2023).
Krishna, S. et al. Glioblastoma remodelling of human neural circuits decreases survival. Nature 617, 599–607 (2023).
Tomaszewski, W. H. et al. Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma. Nat Commun 13, 6483 (2022).
Barron, T. et al. GABAergic neuron-to-glioma synapses in diffuse midline gliomas. Nature 639, 1060–1068 (2025).
Chia, K., Keatinge, M., Mazzolini, J. & Sieger, D. Brain tumours repurpose endogenous neuron to microglia signalling mechanisms to promote their own proliferation. eLife https://doi.org/10.7554/eLife.46912 (2019).
Lu, X. et al. Nerve infiltration of bladder cancer predicts response to immunotherapy. Biochem Biophys Res Commun 761, 151687 (2025).
Reavis, H. D., Chen, H. I. & Drapkin, R. Tumor innervation: cancer has some nerve. Trends Cancer 6, 1059–1067 (2020).
Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer–immune set point. Nature 541, 321–330 (2017).
Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812–30.e14 (2018).
Narote, S. et al. Identification of new immune target and signaling for cancer immunotherapy. Cancer Genet 294–295, 57–75 (2025)..
Martyn, G. V., Shurin, G. V., Keskinov, A. A., Bunimovich, Y. L. & Shurin, M. R. Schwann cells shape the neuro-immune environs and control cancer progression. Cancer Immunol Immunother 68, 1819–1829 (2019).
Lin, C. et al. GDNF secreted by nerves enhances PD-L1 expression via JAK2–STAT1 signaling activation in HNSCC. Oncoimmunology 6, e1353860 (2017).
Rangel-Sosa, M. M., Mann, F. & Chauvet, S. Pancreatic Schwann cell reprogramming supports cancer-associated neuronal remodeling. Glia 72, 1840–1861 (2024).
Kruglov, O. et al. Melanoma-associated repair-like Schwann cells suppress anti-tumor T-cells via 12/15-LOX/COX2-associated eicosanoid production. Oncoimmunology 12, 2192098 (2023).
Zhou, Y., Li, J., Han, B., Zhong, R. & Zhong, H. Schwann cells promote lung cancer proliferation by promoting the M2 polarization of macrophages. Cell Immunol 357, 104211 (2020).
Xue, M. et al. Schwann cells regulate tumor cells and cancer-associated fibroblasts in the pancreatic ductal adenocarcinoma microenvironment. Nat Commun 14, 4600 (2023).
Rocha, B. G. S. et al. Tissue-resident glial cells associate with tumoral vasculature and promote cancer progression. Angiogenesis 26, 129–166 (2023).
Yang, Y. et al. Neurotransmitters: impressive regulators of tumor progression. Biomed Pharmacother 176, 116844 (2024).
Ravindranathan, S. et al. Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma. Nat Commun 13, 6418 (2022).
Passang, T. et al. VPAC2 receptor signaling promotes growth and immunosuppression in pancreatic cancer. Cancer Res 84, 2954–2967 (2024).
Zhang, B. et al. B cell-derived GABA elicits IL-10(+) macrophages to limit anti-tumour immunity. Nature 599, 471–476 (2021).
Schneider, M. A. et al. Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models. Sci Transl Med 13, eabc8188 (2021).
Li, Y. et al. Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite. Cancer Cell 42, 985–1002.e18 (2024).
Bloomer, H., Dame, H. B., Parker, S. R. & Oudin, M. J. Neuronal mimicry in tumors: lessons from neuroscience to tackle cancer. Cancer Metastasis Rev 44, 31 (2025).
Jiang, S. H. et al. GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca(2+) signalling in a GABA-independent manner. Gut 68, 1994–2006 (2019).
Li, B. et al. Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis. Cell 188, 3823–42.e21 (2025).
Xu, P., Zhou, Z. & Geng, Z. Safety monitoring method of moving target in underground coal mine based on computer vision processing. Sci Rep 12, 17899 (2022).
Kenney, M. J. & Ganta, C. K. Autonomic nervous system and immune system interactions. Compr Physiol 4, 1177–1200 (2014).
Xin, Q. et al. Deconstructing the neural circuit underlying social hierarchy in mice. Neuron 113, 444–459.e7 (2025).
Tibensky, M. et al. Topical application of local anesthetics to melanoma increases the efficacy of anti-PD-1 therapy. Neoplasma 70, 375–389 (2023).
Luo, M. et al. Divergent neural activity in the VLPO during anesthesia and sleep. Adv Sci 10, e2203395 (2023).
Ackerman, R. S. et al. The effects of anesthetics and perioperative medications on immune function: a narrative review. Anesth Analg 133, 676–689 (2021).
Massalee, R. & Cao, X. Repurposing beta-blockers for combinatory cancer treatment: effects on conventional and immune therapies. Front Pharmacol 14, 1325050 (2023).
Wang, W. & Cao, X. Beta-adrenergic signaling in tumor immunology and immunotherapy. Crit Rev Immunol 39, 93–103 (2019).
Jain, A., Baracco, R. & Kapur, G. Pheochromocytoma and paraganglioma — an update on diagnosis, evaluation, and management. Pediatr Nephrol 35, 581–594 (2020).
Olar, A., He, D., Florentin, D., Ding, Y. & Ayala, G. Biologic correlates and significance of axonogenesis in prostate cancer. Hum Pathol 45, 1358–1364 (2014).
Mellgard, G. et al. Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors. J Cancer Res Clin Oncol 149, 2833–2841 (2023).
Zhang, F. et al. Impact of beta blockers on cancer neuroimmunology: a systematic review and meta-analysis of survival outcomes and immune modulation. Front Immunol 16, 1635331 (2025).
Rains, S. L., Amaya, C. N. & Bryan, B. A. Beta-adrenergic receptors are expressed across diverse cancers. Oncoscience 4, 95–105 (2017).